Alterations in other cyclin-dependent kinase inhibitors such as CDKN2A have been reported in cutaneous squamous cell carcinomas associated with alterations in ALK in tumors such as lung cancer [38]. This evidence concerns the gene ALK and cutaneous squamous cell carcinoma.